Company intelligence / Profile preview
MediPrint Ophthalmics
San Diego, California, United Statesmediprintlens.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed Phase 2b clinical trial (SIGHT-2) for LL-BMT1 glaucoma treatment. LL-BMT1 trial showed 38% improvement in comfort and 40% reduction in dry eye symptoms. Company is preparing for FDA discussions in 2025 for Phase 3 studies.
- Therapeutic areas
- Ophthalmology
- Modalities
- Drug-eluting contact lenses
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on MediPrint Ophthalmics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MediPrint Ophthalmics.